Cited by 505Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Open access

Kratochwil, Clemens, Bruchertseifer, Frank, Rathke, Hendrik, Bronzel, Marcus, Apostolidis, Christos, Weichert, Wilko, Haberkorn, Uwe, Giesel, Frederik L., Morgenstern, Alfred·2017·Journal of Nuclear Medicine

DOI 10.2967/jnumed.117.191395

Open this paper in CoChat — free account Open PDF

Abstract

The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)–positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time–activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to the physical half-life of 225Ac, assuming instant decay of unstable daughter nuclides. Salvage therapies empirically conducted with 50 (n = 4), 100 (n = 4), 150 (n = 2), and 200 kBq/kg (n = 4) of 225Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. Eight of 14 patients received further cycles in either 2- or 4-mo intervals with identical or deescalated activities. Results: Dosimetry estimates for 1 MBq of 225Ac-PSMA-617 assuming a relative biologic effectiveness of 5 revealed mean doses of 2.3 Sv for salivary glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% α, 0.5% β, and 0.1% photon radiation, respectively. In clinical application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 100 kBq/kg per cycle. At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if therapy was repeated every 2 mo patients experienced additive antitumor effects. Treatment activities of 50 kBq/kg were without toxicity but induced insufficient antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable patients. Conclusion: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.117.191395

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Untitled work
(1997) · PubMed · Cited by 1,541
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Self-citation
German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citation
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citation
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Benešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621
Self-citation
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Giesel, F. L., Hadaschik, B. A., Cardinale, J., Radtke, J. P., Vinsensia, M., Lehnert, W., Kesch, C. V., Tolstov, Y. L., Singer, S., Grabe, N., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 595
Self-citation
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501

Show all 31 references

Sorted by citations

Items 401–500 of 504

The prostatic acid phosphatase in prostate cancer: A novel theranostic target
Seifert, K.-F., Reimann, J., Rust, M., Bögemann, M., Schrader, A. J., Schäfers, M., Bernemann, C., & Backhaus, P. (2026) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2026.03.004 · Cited by 2
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
Ling, S. W., Konijnenberg, M., Segbers, M., Hooijman, E. L., Koolen, S. L. W., de Blois, E., de Jong, L. C., van Puffelen, A. J., de Lussanet, Q. G., Bruchertseifer, F., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271880 · Cited by 2
Self-citation
Harmonization of practice of release of patients after radiopharmaceutical therapy
Чипига, Л. А., Likhacheva, A., Водоватов, А. В., Zvonova, I. A., Stanzhevskiy, A. A., Важенина, Д. А., & Maystrenko, D. N. (2025) · Journal of Radiological Protection · doi:10.1088/1361-6498/adba70 · Cited by 2
State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II
Sancho, L., Roteta, A., Torres, I., de Arcocha, M., Ramos-Membrive, R., Domínguez, M. L., Rosales, J. J., Prieto, E., & Quincoces, G. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2025.500128 · Cited by 2
The Application of Theranostics in Different Stages of Prostate Cancer
Alghazo, O., Eapen, R. S., Koschel, S. G., Cumberbatch, M. G. K., Buteau, J. P., Loh, R., Lawrentschuk, N., & Murphy, D. G. (2021) · Future Oncology · doi:10.2217/fon-2020-1209 · Cited by 2
Dosimetric Principles of Targeted Radiotherapy and Radioimmunotherapy
Vincentis, G. D., Frantellizzi, V., & Pacilio, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_15 · Cited by 2
Side effects of radiocontrast agents and radiopharmaceuticals
Shor, A., Lee, J.-Y. E., & Reci, A. (2023) · Side effects of drugs annual · doi:10.1016/bs.seda.2023.08.003 · Cited by 2
Targeted Alpha Therapy in Cancer Management: Therapeutic Prospects of Nuclear Medicine in Oncology
Mdanda, S., Mdlophane, A. H., Ndlovu, H., Ramonaheng, K., Qebetu, M., Mahapane, J., Kgatle, M., Mzizi, Y. V., Sebatana, R., Cele, Z. E. D., et al. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_195 · Cited by 2
Navigating The Prostate Cancer Frontier: A Bibliometric and Altmetric Analysis of [225Ac]Ac-PSMA Therapy
Al‐Ibraheem, A., Al‐Abdallat, H., Al-Rashdan, R., Abdlkadir, A. S., Sweedat, D. A., Alyasjeen, S. F., Ghesani, M. V., Kairemo, K., & Buscombe, J. R. (2024) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2024.04.004 · Cited by 2
The Synergy Between Ionizing Radiation and Immunotherapy in the Treatment of Prostate Cancer
Sathianathen, N. J., Krishna, S. R., Konety, B. R., & Griffith, T. S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0051 · Cited by 2
Editorial: Radiolabeled Peptides in Cancer Imaging and Therapy—Emerging Isotopes
Malik, N. (2025) · Pharmaceuticals · doi:10.3390/ph18121836 · Cited by 2
Recent advances of Targeted Radioisotope Therapy (TRT) research (PLENARY)
Higashi, T. (2018) · Progress in Nuclear Science and Technology · doi:10.15669/pnst.5.1 · Cited by 1
Leveraging the power of non-radium radionuclide treatments in bone metastases
Thapa, P., & Basu, S. K. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.19.03177-7 · Cited by 1
Alpha Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
Beydağı, G., Selçuk, N. A., & Kabasakal, L. (2023) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2023.0015 · Cited by 1
The Role of Alpha Therapy in Metastatic Castration Resistance Prostate Cancer
Selçuk, N. A., Akçay, K., & Kabasakal, L. (2023) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2023.0014 · Cited by 1
Small Molecules as Vectors for Radiopharmaceutical Therapy
Rowe, S. P., Werner, R. A., Garg, T., Gafita, A., Voter, A. F., Sadaghiani, M. S., Markowski, M. C., Paller, C. J., Zalutsky, M. R., Sólnes, L. B., et al. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_17 · Cited by 1
A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma
Voter, A. F., Amindarolzarbi, A., Shen, C. J., Wang, J. H., Kang, H., Sharma, R., Sólnes, L. B., Pomper, M. G., Bishop, J. A., Rowe, S. P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01515-z · Cited by 1
Optimizing [ 212 Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts
Høyvik, A. J. K., Stenberg, V. Y., Liukaityte, R., Repetto‐Llamazares, A. H. V., Peng, Q., Wangen-Riise, R., Wiig, E., Ma, L., Revheim, M.-E. R., & Juzeniene, A. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270444 · Cited by 1
Nuclear excitation functions for medical isotope production: Targeted radionuclide therapy via natIr ( d , x ) 193mPt
Ekeberg, H. L. O., Voyles, A. S., Basunia, M. S., Batchelder, J. C., Bernstein, L. A., Bleuel, D. L., Li, K. C. W., Martinsen, E. M., Matthews, E. F., Morrell, J. T., et al. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112311 · Cited by 1
Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks
Ketchemen, J. P., Ahenkorah, S., Nwangele, E., Malaza, S. S. P., Ooms, M., Cardinaels, T., Leekens, S., Cleeren, F., & Fonge, H. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00408-w · Cited by 1
Estimation of absorbed doses in computational mouse and human phantoms receiving 229 Th-derived free 225 Ac
Jang, J. S., Tanaka, T., Ozeki, A. N., Imura, R., Higaki, S., Kobayashi, M., Miao, Q., Akimitsu, N., Kumakura, Y., Nakano, T., et al. (2026) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ae3b04 · Cited by 1
A Phase 0 Imaging Trial of [ 203 Pb]Pb-VMT-a-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [ 212 Pb]Pb-VMT-a-NET
Graves, S. A., Bushnell, D. L., Schultz, M. K., Jain, S., Bodeker, K. L., & Menda, Y. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270083 · Cited by 1
IGF2R-Targeted Alpha Therapy of Osteosarcoma Enabled by Conjugated [ 225 Ac]Ac-Macropa-PEG 4 -IF3
Shah, S. Q., Santos‐Oliveira, R., İlem‐Özdemir, D., & Shabnam, M. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00125 · Cited by 1
Design, Synthesis, and Evaluation of [ 68 Ga/ 177 Lu]-Labeled TSPO-Targeting Radioligands for PET/CT Diagnosis and Radionuclide Therapy of Brain Tumor
Wang, X., Zhang, S., Li, Y., Liu, C., Wu, J., Wu, Y., Hu, Q., Liu, W. T., Lu, Q., Hu, X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03527 · Cited by 1
PSMA Therapy Grey Zones: Actinium, Lutetium, or Terbium for the Future of Radioligand therapy?
Dragonetti, V., Mattana, F., & Ceci, F. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.05.024 · Cited by 1
Recherche de facteurs de risque de la thrombopénie induite par le 177Lu-DOTATATE dans le bilan de suivi standard
Ferrara, R., Charrier, N., Darréon, J., Giraud, R., Reichert, T., Mourre, F., Oziel-Taïeb, S., Brenot-Rossi, I., & Ouk, D. (2020) · Médecine Nucléaire · doi:10.1016/j.mednuc.2019.12.002 · Cited by 1
Fundamentals of Radiation Safety and Dosimetric Approach in Radionuclide Therapy Applications
Kıraç, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-97220-2_3 · Cited by 1
Targeted alpha therapy in prostate cancer: review of available agents in clinical practice
Ndlovu, H., Lawal, I. O., Kabunda, J., Kaoma, C. A., Mashigoane, K., Knoesen, Z., RAMONAHENG, K., Sibiya, S. M., Mdlophane, A. H., Mdanda, S., et al. (2025) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.25.03642-8 · Cited by 1
Immune modulation following α and β − radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model
Ceuppens, H., Ridder, K. D., Ertveldt, T., Zeven, K., de Mey, W., Antunes, A. R. P., Navarro, L., Dumauthioz, N., Lahoutte, T., Debacker, J. M., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2540054 · Cited by 1
Radiometabolic Therapy of Bone Metastases
Paone, G., & Nitzsche, E. U. (2019) · Springer eBooks · doi:10.1007/978-3-030-17494-1_6 · Cited by 1
Prostaatspecifiek membraanantigeen radioligandtherapie met alfastralers, een review
Privé, B. M., van Gemert, W. A., Nagarajah, J., Mehra, N., Gerritsen, W. R., van Oort, I. M., Gotthardt, M., Heskamp, S., & Janssen, M. J. R. (2020) · Tijdschrift voor Urologie · doi:10.1007/s13629-020-00301-y · Cited by 1
Theranostic Innovation by Humane N-of-One Cancer Care in Real-World Patients
Turner, J. H. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0198 · Cited by 1
Molekulare Radiotherapie mit neuen Radiopharmaka: Präzisionsonkologie zur personalisierten Patientenbehandlung
Langbein, T., Kulkarni, H., Zhang, J., & Baum, R. P. (2018) · Der Nuklearmediziner · doi:10.1055/a-0671-5500
Uroonkologische und nuklearmedizinische Behandlungsmöglichkeiten beim metastasierten, kastrationsresistenten Prostatakarzinom (mCRPC)
Kroenke, M., Eiber, M. J., & Tauber, R. (2019) · Radiopraxis · doi:10.1055/a-0942-7512
Radioimmunoimaging and Targeted Therapy
Yin, Y., & Rowe, S. P. (2019) · Springer eBooks · doi:10.1007/978-981-13-7458-6_13
Emerging Vistas in Alpha Therapy—PSMA and Soft-Tissue Metastases
Oyen, W. J. G. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.07.001
Differences in edge artifacts between 68Ga- and 18F-PET images reconstructed using point spread function correction
Amakusa, S., Matsuoka, K., Baba, S., Yoshida, T., & Sasaki, M. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001079
Research and Development of Targeted Radioisotope Therapy
Higashi, T. (2019) · Journal of the Atomic Energy Society of Japan · doi:10.3327/jaesjb.61.2_133
Radionuclide therapy with alpha-emitters
Da, D., & Sd, M. (2019) · Radiation Diagnostics Radiation Therapy · doi:10.37336/2707-0700-2019-4-4
Sialoscintigraphy – Shopworn or Bestselling? A Traditional Procedure with New Prominent Role in Theranostics and Immuno-Oncology
Kreppel, B., Gaertner, F. C., & Essler, M. (2020) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1152-2279
Obtenção de kit de PSMA-617 para pronta marcação com lutécio-177 e sua avaliação na aplicabilidade no tratamento do câncer de próstata
Boas, C. A. W. V. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.85.2020.tde-23122020-094716
Prostate Cancer Theranostics
Rowe, S. P., Sadaghiani, M. S., Werner, R. A., Higuchi, T., Derlin, T., Sólnes, L. B., & Pomper, M. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00087-9
Targeted radionuclide therapy in bone cancer
Bruland, Ø. S., Revheim, M. E., Larsen, R. H., & Juzeniene, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00030-x
Targeted Radionuclide Therapy and Immunotherapy of Metastatic Prostate Cancer
Jadvar, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_18
Nuclear medicine therapy of prostate cancer: State of the art and future perspectives
Boshomane, T. M. G., Lawal, I. O., & Sathekge, M. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00038-7
Cabazitaxel/docetaxel/PSMA 617
(2017) · Reactions Weekly · doi:10.1007/s40278-017-38595-8
Radionuclide Therapy in Prostate Cancer
Acar, E., Bekiş, R., & Polack, B. (2022) · Springer eBooks · doi:10.1007/978-3-030-97220-2_15
Impact of Alpha-Radiotherapy on the Tumor Microenvironment
Allard, M., Perrin, J., Guilloux, Y., Kraeber‐Bodéré, F., Chérel, M., & Gaschet, J. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_116-1
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_303-1
Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA?
Lawal, I. O., Morgenstern, A., Knoesen, O., Vorster, M., Bruchertseifer, F., & Sathekge, M. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-33533-4_26
Self-citation
Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC
Jadvar, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-33533-4_15
Molecular radionuclide therapy-induced salivary gland toxicity: an unappreciated threat to patients’ quality of life?
Vöö, S. A., Mercadante, V., Riaz, S., Algodayan, S., Scott, C. J., Priftakis, D., Shephard, M. K., & Bomanji, J. B. (2024) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001839
Gondolatok a prosztatarákos betegek csontáttéteinek szisztémás kezeléséről
Pikó, B., Kiss, A., Bassam, A., Molnár, Z., Rus-Gal, P. O., Szeberényi, T., & Mészáros, T. (2022) · Magyar urológia · doi:10.22591/magyurol.2022.3.pikob.107
Calculation of alpha particle single-event spectra using a neural network
Alkhani, L., Luce, J., Gabiña, P. M., & Roeske, J. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394671
The possibilities of prostate cancer radioligand therapy with low-molecular-weight PSMA inhibitors labeled with actinium-225: a review
Тищенко, В. К., Крылов, В. В., Kochetova, T. Y., Shurinov, A. Y., Власова, О. П., Shegai, P., Иванов, С. А., & Каприн, А. Д. (2025) · Diagnostic radiology and radiotherapy · doi:10.22328/2079-5343-2024-15-4-40-56
General Toxic Properties of the Radiopharmaceutical 225Ac-DOTA-PSMA
Тищенко, В. К., Pankratov, A. A., Власова, О. П., Demyashkin, G. A., Федорова, А. В., Plotnikova, E. A., Venediktova, Y. B., Orlenko, S. P., Степченкова, Е. Д., Ostroukhov, A. A., et al. (2024) · Physics of Atomic Nuclei · doi:10.1134/s1063778824100508
Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II
Sancho, L., Roteta, A., Torres, I., de Arcocha, M., Ramos-Membrive, R., Domínguez, M. L., Rosales, J. J., Prieto, E., & Quincoces, G. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2025.500128
Clinical Experience in 225Ac-PSMA
Kairemo, K. (2025) · Springer eBooks · doi:10.1007/978-3-031-90337-3_15
2. Radiopharmaceuticals for Targeted Radiotherapy
Hasegawa, K. (2025) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.25-0501
Energy deposition and receptor saturation set a tumour size threshold for radiopharmaceutical therapy: insights from a pharmacokinetic–tumour dynamics modelPreprint
Mollaheydar, E., Saboury, B., Rahmim, A., & Cytrynbaum, E. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.28.656722
Alpha-particle Emitting Radiopharmaceuticals in Targeted Therapy and Diagnostics: Challenges and Opportunities
Koniar, H., & Schaffer, P. C. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00056
Dosimetry Methods for Radiopharmaceuticals
Rana, N., Chopra, S., & Kaur, K. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00159
Preemptive denaturing of 233U for more secure 225Ac production
Haas, D. A. (2025) · Nuclear Science and Technology Open Research · doi:10.12688/nuclscitechnolopenres.17681.1
A review of PSMA-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
Farbod, A., Farzanehfar, S., Beheshti, M., Delpassand, E. S., Hashmi, M. J., Aghanejad, A., Eppard, E., & Vahidfar, N. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10394-7
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Toyohara, J., Elsinga, P., Todde, S., Li, X., Aime, S., Szymański, W., van der Meulen, N., Cleeren, F., Schirrmacher, R., Yang, H., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00387-y
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_303
Impact of Alpha-Radiotherapy on the Tumor Microenvironment
Allard, M., Perrin, J., Guilloux, Y., Kraeber‐Bodéré, F., Chérel, M., & Gaschet, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_116
Recent evidence of theranostics and its perspectives on clinical advances and emerging approaches
Rawal, K. B., Kolte, K., Chand, S., Sutar, A. S., & Singh, R. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34199-1.00004-1
Sudy on the Extraction of High-Purity 226 Ra Solutions from Uranium OrePreprint
Yang, H., Wang, C., Chen, J., Wei, L., Ma, W., Zhang, C., Zhang, J., Zhao, X., & Tang, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-7658755/v1
Additional file 1 of The effect of eating on the uptake of PSMA ligands in the salivary glands
Mohan, V., Bruin, N. M., van de Kamer, J. B., Sonke, J., & Vogel, W. V. (2021) · Figshare · doi:10.6084/m9.figshare.16683087
Additional file 1 of Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice
Ukon, N., Zhao, S., Washiyama, K., Oriuchi, N., Tan, C., Shimoyama, S., Aoki, M., Kubo, H., Takahashi, K., & Ito, H. (2020) · Figshare · doi:10.6084/m9.figshare.12991801
Additional file 1 of Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
Rumiantcev, M., Li, W. B., Lindner, S., Liubchenko, G., Resch, S., Bartenstein, P., Ziegler, S. I., Böning, G., & Delker, A. (2023) · Figshare · doi:10.6084/m9.figshare.24124029
Additional file 1 of Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
Felber, V. B., Valentin, M. A., & Wester, H.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14129120
Additional file 1 of A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [68Ga]Ga-PSMA-11
Huang, S. S.-L., DiFilippo, F. P., Lindner, D. J., & Heston, W. D. W. (2024) · Figshare · doi:10.6084/m9.figshare.26674658
Current status of nanotheranostics in precision medicine
Saddique, M. A. B., Amjad, M. D., Tahir, H., & Sajid, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34671-2.00019-0
Future Horizons in Nuclear Medicine
Alqahtani, M. M., & Malik, M. M. U. D. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813543125010018
Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of [225Ac]Ac/[177Lu]Lu-PSMA-therapy
Sheikh, G. T., Siegmund, S. C., Widjaja, L., Fouladgar, S. T., Delker, A., Casuscelli, J., Unterrainer, L. M., Werner, R., & Zacherl, M. J. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07744-8
Production of Diagnostic and Therapeutic Radionuclides with Uranium and Thorium Molten Salt Fuel Cycles
Moss, C. E., Chvála, O., & Hartanto, D. (2026) · Journal of Nuclear Engineering · doi:10.3390/jne7010009
Clinical research analysis of [225Ac]Ac-PSMA-617 therapy for [177Lu]Lu-PSMA-refractory metastatic castration-resistant prostate cancer
Rao, Z., Ma, J., Yangqing, J., Yang, W., Zhang, F., Hu, M., Zhang, C., & Chen, Y. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07778-6
Metal–Arene Reductants: A Strategic Tool for Synthesizing Monometallic to Intermetallic Nanostructures
Lakharwal, P., Patel, P. C., & Byun, H.-S. (2026) · Chemistry of Materials · doi:10.1021/acs.chemmater.6c00412
Monte Carlo modeling of targeted radionuclide therapy of micrometastases
Alcocer‐Ávila, M. (2021) · theses.fr (ABES) · doi:10.70675/d9d14d84z2d27z42c8z90e8zdd4b482de12f
Impact de la radiothérapie interne vectorisée alpha sur le microenvironnement tumoral
Perrin, J. (2021) · theses.fr (ABES) · doi:10.70675/31c91866z101fz4e07zbde2z6887a8fdba6d
Synthese et evaluation de traceurs peptidiques heterobivalents pour l’imagerie moleculaire
Bailly, T. (2022) · theses.fr (ABES) · doi:10.70675/ff7dcc7dzaeecz4574z851bzb468baa1e15b
Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer
Ketchemen, J. P., Monzer, A., Njotu, F. N., Babeker, H., Tikum, A. F., Nwangele, E., Henning, N. W., Hassani, N., Ngong, A. F., Doroudi, A., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03393-2
Publication trends and knowledge structure of prostate-specific membrane antigen radioligand therapy for prostate cancer: a bibliometric analysis, 2015–2025
Long, H., Qiao, X.-H., Li, X. J., Kong, X., & Liu, Q.-W. (2026) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002193
Conceptual design of a mass separation system for high-purity actinium-225
Dong, Q., Li, Y., Jing, H., Wang, P., Tan, Z., Liu, J., Wang, Y., Dai, M., & Guo, Y. (2026) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2026.114190
RADIATION THERAPY AS A POTENTIAL APPROACH TO ENHANCING THE EFFICACY OF TARGETED RADIONUCLIDE THERAPY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Baryshnikov, I. A., Sychev, P. V., Mayakova, E. V., Kaydash, Y. A., Shaydiyarova, E. L., & Belostotskiy, A. V. (2026) · Ulyanovsk Medico-biological Journal · doi:10.34014/2227-1848-2026-2-6-25
Formulation and Physiochemical Characterization of PLGA–Chitosan–Folic Acid Nanoparticles Loaded with [225Ac]Ac-PSMA617-TFA for Targeted Alpha Therapy of Prostate Cancer
Mzizi, Y. V., Witika, B. A., Ndlovu, H., Shungube, M., Makoni, P. A., Sibiya, S. M., Mdlophane, A. H., Ramonaheng, K., Sathekge, M. M., & Mdanda, S. (2026) · Radiation · doi:10.3390/radiation6030027
Tumor microenvironment-mediated hematologic toxicity of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer: mechanisms, risk stratification, and clinical management
Wang, Z., 輝, 小., Wang, B., Tang, W., Liang, G., & Wu, T. (2026) · World Journal of Urology · doi:10.1007/s00345-026-06620-w
Quantitative Imaging Evaluation of Structural and Densitometric Changes in Major Salivary Glands After 177Lu PSMA Radioligand Therapy
KÖYLÜCE, N., & Demir, F. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02266-1
Efficacy of Actinium-225–Labeled Fully Human Anti–MUC-16 Radioimmunoconjugate against MUC-16–Positive Ovarian and Pancreatic Ductal Adenocarcinoma Xenograft Models
Babeker, H., Nwangele, E., Monzer, A., Ketchemen, J. P., Bato, K. E. M., Njotu, F. N., Tikum, A. F., Mercado, T. R., Doroudi, A., Torlakovic, E., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0326
[225Ac]Ac-iPSMA Radiopharmaceuticals for Targeted Alpha Therapy: Design, Synthesis, and Preclinical Evaluation
García-Arce, D., Luna‐Gutiérrez, M., Cruz-Nova, P., Limón, A. M. V., Jiménez‐Mancilla, N., Aranda‐Lara, L., Azorin‐Vega, E. P., Morales-Ávila, E., Rodríguez-López, P., Santos‐Cuevas, C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177785
Expanding the Theranostic Toolbox: Emerging Therapeutic Isotopes
Rodríguez, C. M. A., Liles, G., Lapi, S. E., & Lewis, J. S. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269487
Targeted alpha therapy for recurrent high-grade glioma with [²²⁵Ac]-PSMA: a new theranostic approach
Sayman, H. B., Aras, Ö., Hekim, M. V., Saglam, K., Akgün, E., & Dinçbaş, F. Ö. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08194-6
PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides
Lin, E. T. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02302-0
Clinical translation of targeted alpha therapy: safety, dosimetry, radiation protection, and regulatory considerations
Jokar, N., Pashazadeh, A., Juweid, M. E., Najdian, A., Jafari, E., Mottaghy, F. M., Assadi, M., & Sathekge, M. M. (2026) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2026.09.002
Optimising syringe shields for actinium-225: beta dominance of the hand dose and the role of the outer shield surfacePreprint
SIVAN, A. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7624296
Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers
Ebrahimifard, A., Bagheri, S., Wang, Q., Shamami, A. H., Fazio, P. D., Eilsberger, F., Müller, L., Luster, M., Librizzi, D., & Yousefi, B. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209330
Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides
Zulfiqar, H., Waqas, M., & Ali, I. (2026) · RSC Advances · doi:10.1039/d6ra06959b
BindingDB Entry 50018661: PSMA-targeted low-molecular double conjugates for diagnostics and therapy.
BindingDB (2024) · UC San Diego · doi:10.7270/q23j3j52

Authors: Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A.
Affiliations: University Hospital Heidelberg (DE)
European Commission (BE)
ABX-CRO Advanced Pharmaceutical Services (Germany) (DE)
Pathologisches Institut (DE)
German Cancer Research Center (DE)
ORCID: Kratochwil, Clemens
Bruchertseifer, Frank
Rathke, Hendrik
Apostolidis, Christos
Weichert, Wilko
Haberkorn, Uwe
Giesel, Frederik L.
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2017-04-13
Volume: 58
Issue: 10
Pages: 1624-1631
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.117.191395
OpenAlex: W2606187374
Cited by: 505
References: 31
Citations by year: 2026: 35 · 2025: 60 · 2024: 48 · 2023: 36 · 2022: 53 · 2021: 83 · 2020: 57 · 2019: 61 · 2018: 57 · 2017: 14
FWCI: 39.13
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Joint Research Centre (European Commission) (submittedVersion)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: metastatic castration-resistant prostate cancer, dosimetry, 177Lu-PSMA-617, xerostomia, salvage therapy, PSA response, treatment toxicity
MeSH terms: Actinium, Aged, Alpha Particles, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Neoplasm Metastasis, Radiometry, Radiotherapy Dosage, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks